GSK shares slide on weak vaccine sales, restructuring charges despite Q3 beat

GSK reported a 19% decline in pre-tax profit to £1.9bn for Q3, hit by weaker vaccine sales and £318m in restructuring charges, with more costs expected. Despite better-than-expected results, shares fell as investors focused on the deteriorating outlook, including looming patent loss for its HIV drug. This signals continued pressure on GSK's growth profile and may weigh on sector sentiment.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works